Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

More on the new study.

Published On: 2 June 2023

  • Inhalation Sciences Sweden

    In Flemingsberg, we have access to the advanced labs that we need, and it offers the right facilities we need to expand.

  • Mando Group

    Our research and development has been conducted in co-operation with both KI and Karolinska University Hospital here in Flemingsberg. The positive climate on Campus Flemingsberg encourages original ideas and co-operation.

  • NextCell Pharma

    Flemingsberg is entirely the right place for us due to its closeness to co-operation partners and the clinical research at Karolinska University Hospital.

  • Sprint Bioscience

    Flemingsberg offers us the opportunity to grow and provides a good working environment for our employees. Other advantages are the proximity to research at Karolinska Institutet and the clinical research at Karolinska University Hospita